Molecular features of thymidine analogues governing the activity of human thymidine kinase

Modified uridines seem to be able to work as hypoxic tumour cell radiosensitisers. Before they sensitise cells to ionising radiation, they have to be incorporated into the genomic DNA and the latter process has to be preceded by the phosphorylation of the modified uridine, which in human cells is executed by human thymidine kinase 1 (hTK1). In the current study, we present the quantitative structure-activity relationship (QSAR) model allowing to identify and understand the molecular features of nucleoside derivatives governing the hTK1 kinase activity. The developed model meets all requirements of a reliable QSAR model and is based on only two molecular properties: the shape of the nucleoside determined by atom substitutions and the ability of the molecule to intermolecular interactions with the enzyme. These results have important implications for the rational designing of new hTK1 substrates and should significantly reduce the time and cost of studies on new radiosensitisers.